Tag: Nivolumab combination approval

Home / Nivolumab combination approval

Categories

Nivolumab in combination with cisplatin and gemcitabine is approved by the USFDA for unresectable or metastatic urothelial carcinoma

March 2024: The Food and Drug Administration has granted approval for the use of nivolumab (Opdivo, Bristol-Myers Squibb Company) in conjunction with cisplatin and gemcitabine as the initial treatment...
nivolumab-combination-approval

Scan the code